References of "Abboud, Dayana"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDiscovery and pharmacological characterization of succinate receptor (SUCNR1/GPR91) agonists
Geubelle, Pierre ULg; Gilissen, Julie; Dilly, Sebastien et al

in British Journal of Pharmacology (in press)

Background and Purpose The succinate receptor (SUCNR1 or GPR91) has been described as a metabolic sensor that may be involved in homeostasis. Notwithstanding its implication in important (patho ... [more ▼]

Background and Purpose The succinate receptor (SUCNR1 or GPR91) has been described as a metabolic sensor that may be involved in homeostasis. Notwithstanding its implication in important (patho)physiological processes, the function of SUCNR1 has remained elusive because no pharmacological tools were available. We report on the discovery of the first family of synthetic potent agonists. Experimental Approach We screened a library of succinate analogues and analysed their activity on SUCNR1. In addition, we modelled a pharmacophore and a binding site for the receptor. New agonists were identified based on the information provided by these two approaches. Their activity was studied in various bioassays, including measurement of cAMP levels, [Ca2+]i mobilisation, TGF-α shedding and recruitment of arrestin 3. The in vivo impact of SUCNR1 activation by these new agonists was evaluated on rat blood pressure. Key Results We identified cis-epoxysuccinic acid and cis-1,2-cyclopropanedicarboxylic acid as agonists with an efficacy similar to the one of succinic acid. Interestingly, cis-epoxysuccinic acid was characterized by a 10 to 20 fold higher potency than succinate on the receptor. For example, cis-epoxysuccinic acid reduced cAMP levels with a pEC50 = 5.57 ± 0.02 (EC50 = 2.7 μM) as compared to succinate pEC50 = 4.54 ± 0.08 (EC50 = 29 μM). The rank order of potency of the three agonists was the same in all bioassays tested. In vivo, cis-epoxysuccinic and cis-1,2-cyclopropanedicarboxylic acid increased rat blood pressure to the same extent as succinate did. Conclusions and Implications We provide new agonist tools for SUCNR1 that should facilitate further research on this understudied receptor. [less ▲]

Detailed reference viewed: 31 (4 ULg)
Full Text
Peer Reviewed
See detailChemokine neutralization as an innovative therapeutic strategy for atopic dermatitis
Abboud, Dayana ULg; Hanson, Julien ULg

in Drug Discovery Today (in press)

Detailed reference viewed: 23 (2 ULg)
Peer Reviewed
See detailSmall molecule ligands for the orphan GPR27
Dupuis, Nadine ULg; Franssen, Delphine ULg; Laschet, Céline ULg et al

Poster (2016, September 26)

Background G protein-coupled receptors (GPCRs) are involved in many physiological processes and constitute the target of around 30% of marketed therapies. Nonetheless, ~100 human GPCRs have no known ... [more ▼]

Background G protein-coupled receptors (GPCRs) are involved in many physiological processes and constitute the target of around 30% of marketed therapies. Nonetheless, ~100 human GPCRs have no known ligand and are designated as "orphan". This project focuses on GPR27, a rhodopsin-like alpha orphan of the SREB family (Super conserved Receptors Expressed in the Brain), presumably involved in the regulation of insulin secretion [1]. Methods In order to identify small molecules activating GPR27, we developed a firefly luciferase complementation assay (based on [2]) to assess the binding of ß-arrestin2 to the activated GPCR. To increase the affinity for and strengthen the interaction with ß-arrestin2, a GPR27-V2R chimera has been used for library screening. Results Small molecules activating GPR27-V2 have been identified in the DiverSetTM library (ChemBridge). After exclusion of non-specific activities using another unrelated GPCR, two compounds sharing a common scaffold with activity in the low micromolar range were selected for further investigations. We confirmed their agonist profile by performing complete concentration-response curves on our arrestin complementation assay as well as orthogonal assays. These compounds show good specificity being inactive on GPR85-V2 and GPR173-V2 (the two other SREB members). With these original tools, we characterized the recruitment of ß-arrestin2 to activated GPR27 WT. Conclusion We identified small molecule ligands for GPR27 that will serve as valuable tools for studying the pharmacology of GPR27 as well as its physiological roles, for example in insulin secretion. 1 Ku G.M., Pappalardo Z., Luo C.C., German M.S., McManus M.T. An siRNA Screen in Pancreatic Beta Cells Reveals a Role for Gpr27 in Insulin Production. PLoS genetics. 2012, 8, e1002449. 2 Takakura H., Hattori M., Takeuchi M., Ozawa T. Visualization and Quantitative Analysis of G Protein-Coupled Receptor−β-Arrestin Interaction in Single Cells and Specific Organs of Living Mice Using Split Luciferase Complementation. ACS Chem. Biol. 2012, 7, 901−910. [less ▲]

Detailed reference viewed: 55 (3 ULg)
Full Text
See detailTargeted mutagenesis of orphan GPCRs of the SREB family
Laschet, Céline ULg; Dupuis, Nadine ULg; Soni, Arvind ULg et al

Poster (2016, September)

Detailed reference viewed: 13 (8 ULg)